このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

一般的な実践における抗菌薬管理の最適な実装 (OPTIMAS-GP)

2026年11月16日 更新者:Andrew Bonney、University of Wollongong

一般的な実践(Optimas-GP)研究における抗菌薬スチュワードシップの最適な実装:ハイブリッドタイプ3の実装試験

This trial aims to increase the use of antimicrobial stewardship resources when treating patients with respiratory tract infections. This trial is set in Australian general practices (family medicine or primary care).

The main question it aims to answer is which type of implementation activities increase the use of antimicrobial stewardship resources. Researchers will compare doctors who receive face-to-face implementation activities (the Integrated Network group) to those who received virtual or online activities (the Virtual Network group). The primary hypothesis is that there will be a difference in how often interventions are used

Participating doctors will be asked to record how often they use antimicrobial stewardship resources and which interventions they prefer. Participating practices will also provide researchers data on how many patients the doctors see.

Patients with respiratory tract infections who saw a participating doctor will be asked to give feedback on their experience using surveys. A subgroup of doctors, practice staff, and patients will interviewed about their experience in the study.

調査の概要

詳細な説明

SUMMARY The OptimasGP study is a two-arm superiority cluster-randomised Hybrid type 3 pragmatic implementation trial to promote the use of antimicrobial stewardship (AMS) interventions by doctors in general practice treating adults with respiratory tract infections.

The implementation strategies used in the trial will be delivered using a Virtual Network (arm 1) and Integrated Network (arm 2) approach. Data collection will collected for five months during winter for the baseline period, followed by implementation activities, and five months in the following winter post-activities.

The primary study outcome is AMS intervention use per 100 consultations. Secondary objectives are based on the RE-AIM framework for reach, efficacy, implementation, adoption, and maintenance of the implementation.

SETTING The study sites for the implementation study comprise 40 general practices across New South Wales, Queensland, Tasmania, and Victoria in Australia.

PARTICIPANTS Participants include 120 general practice (family practice) doctors, 40 practice staff, and patients with respiratory tract infections. Informed consent will be obtained from participating doctors and practice staff in written form by members of the research team. Approximately half of participants will be recruited in 2025, with the remainder recruited in 2026.

Patients will be sent invitations to participate in the study by practice staff via SMS. For patient surveys, completion of surveys will constitute tacit consent. For patients in the case-studies sub-group, informed consent will be obtained in written form by members of the research team.

There are two subgroups. In the first subgroup, six sites from each arm will be elected for the nested case-study (individual semi-structured interviews). For each site, interviewers will construct case studies consisting of 6-8 participants (e.g., 2 doctors, 1-2 practice nurses, 1 practice manager, and 4 ARI patients per case).

In the second subgroup, 3-6 sites per arm (6-9 doctors) will be provided with FebriDx point of care tests to identify if respiratory tract infections are bacterial or viral in origin. These tests have been approved by the USA FDA (K230917) and by the Australian Therapeutic Goods Administration (ref 346636).

Recruitment and retention will be facilitated by payments to participants.

INTERVENTION RESOURCES Participating doctors will be provided AMS interventions in an online AMS Toolbox (see the latest version at https://redcap.uow.edu.au/redcap/surveys/?s=37HKC3KFMLED7PY7) which they may use when treating eligible patients. The Toolbox will contain AMS interventions resource for shared decision-making between doctors and patients, delayed prescribing, and clinical decision support (including guidance for using FebriDx point of care devices for relevant members of the subgroup).

IMPLEMENTATION ACTIVITIES Both arms will complete ~7 hours of implementation activities. These activities will be provided by MedCast, an established provider of ongoing health professional education in Australia.

Participants in the Virtual arm will receive online self-paced education modules, guided self-audit and reflection regarding antimicrobial stewardship and use of AMS Toolbox components, and reinforcement podcasts.

Participants randomised to the Integrated Network arm will receive education delivered by live interactive online webinar-based sessions, peer-group audit and reflection, and reinforcement online forum participation.

DATA COLLECTION Doctors complete data entry using the AMS Toolbox by selecting if they used an intervention, which intervention was used, and whether an antibiotic was prescribed for immediate use, delayed use, or not prescribed. In addition, the number of patients seen by each doctor will be collected based on a fortnightly record of practice records using surveys.

Demographic data will be collected using online surveys.

Patients will completed patient-reported outcome measures and patient reported experience measures using online surveys. Interviews of the nested-case study sub-group will be qualitative in nature.

All surveys will using REDCap (Research Electronic Data Capture) forms hosted at the University of Wollongong.

RISKS As this study has a low risk of harm or death, and as no interim analyses are planned, the study will not have a Data Safety Monitoring Board. Harms will be recorded through PROMs and direct reports from participating doctors. Harms such as re-consultations and hospitalizations reported to the research team will be discussed with an independent data monitor. This monitor can cease the study at any time if concerns arise. No interim analysis is planned and thus no stopping guidelines are provided.

研究の種類

介入

入学 (実際)

111

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • New South Wales
      • Wollongong、New South Wales、オーストラリア、2500
        • University of Wollogongong
    • Queensland
      • Gold Coast、Queensland、オーストラリア、4226
        • Bond University
    • Tasmania
      • Hobart、Tasmania、オーストラリア、7005
        • University of Tasmania
    • Victoria
      • Melbourne、Victoria、オーストラリア、3800
        • Monash University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Study sites

Inclusion Criteria:

  1. at least two GPs per practice consent to be in the study,
  2. that at least one member of practice staff consents to be in the study
  3. that a staff member from the site will be available to provide 90 minutes per fortnight of administrative support for the study. There are no exclusion criteria in addition to this.

Exclusion Criteria: None

Participating doctors and healthcare workers

Inclusion criteria:

1) Working at a participating practice for at least two days a week. Exclusion criteria : None

Patients completing patient reported outcome measure survey

Inclusion criteria:

  1. patients consulted with a participating GP for a RTI,
  2. patients re-consulted with a GP or was hospitalized. Exclusion criteria: None

Patient reported experience measures survey

Inclusion criteria:

1) patient consulted with a participating GP for an RTI. Exclusion criteria: None

Patients participating in interviews as part of the nested case studies

Inclusion criteria:

  1. consulted with a participating GP for a RTI,
  2. completed a patient survey,
  3. able to read and speak English Exclusion criteria: None

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Virtual network activities

Participants randomised to the Virtual arm will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (~7 hours).

Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (~7 hours).

Participants in the Virtual Newtwork arm will primarily receive these interventions online.

実験的:Integrated network activities

Participants randomised to the Integrated Network arm will receive antimicrobial intervention education delivered by live interactive online webinar-based sessions, peer-group audit and reflection, and reinforcement online forum participation.

Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (~7 hours).

Participants in the Integrated Network arm will primarily receive these interventions face-to-face and active online activities.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in use of antimicrobial interventions per 100 consults
時間枠:From baseline for 5 months, from post intervention for 5 months

This score is derived from the number of times an intervention is used (measured using the AMS Toolbox online form) divided by the number of participants a doctor sees (measured using an audit). Measuring periods are fortnightly.

The eligible range is 0-100, with higher values indicating a better outcome.

From baseline for 5 months, from post intervention for 5 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Reach: Number enrolled - Doctors
時間枠:Enrolment

Enrolment

Enrolment rates of doctors will be determined for doctors by the number of online consents completed via Redcap. Higher numbers indicate better outcomes.

Enrolment
Reach: Representativeness of practices
時間枠:Baseline

A survey of practice size and location will be conducted.

Baseline
Reach: Completions - Doctors
時間枠:5 months post intervention

Completion rates of doctors will be determined by recording participant completion rates across all phases of the trial.

5 months post intervention
Reach: Representativeness of participating doctors and staff
時間枠:Baseline.

A survey of participating doctors and staff will be conducted to measure demographic and workplace variables.

Baseline.
Reach: Representativeness of patients
時間枠:From baseline up to 5 months, from post intervention up 5 months

Brief demographic questions will be asked of patients completing online surveys.

From baseline up to 5 months, from post intervention up 5 months
Effectiveness: Change in intervention use per 100 RTI consults
時間枠:From baseline for 5 months, from post intervention for 5 months

This score is derived from the number of times an intervention is used (measured using the AMS Toolbox online form) divided by the number of patients with a respiratory tract infection (RTI) a doctor sees (measured using an audit). Measuring periods are fortnightly. The eligible range is 0-100, with higher values indicating a better outcome.

From baseline for 5 months, from post intervention for 5 months
Effectiveness: Change in antibiotics prescribed per 100 RTI consults
時間枠:From baseline for 5 months, from post intervention for 5 months

This score is derived from the number of times an antibiotic is prescribed (measured using the AMS Toolbox online form) divided by the number of patients with a respiratory tract infection (RTI) a doctor sees (measured using an audit). Measuring periods are fortnightly. The eligible range is 0-100, with higher values indicating a worse outcome.

From baseline for 5 months, from post intervention for 5 months
Effectiveness: Change in antibiotic prescriptions given for RTIs (self-report)
時間枠:From baseline for 5 months, from post intervention for 5 months

This score is derived from the number of times an antibiotic is dispensed (measured using the AMS Toolbox online form) divided by the number of patients with an RTI a doctor sees (measured using AMS Toolbox). The eligible range is 0-100, with higher values indicating a worse outcome.

From baseline for 5 months, from post intervention for 5 months
Effectiveness: Total antibiotics prescribed per 100 consults
時間枠:From baseline for 5 months, from post intervention for 5 months

This score is derived from the total number of times an antibiotic is prescribed (measured using the AMS Toolbox online form) per consults with patients.

The eligible range is 0-100, with lower values indicating a better outcome.

From baseline for 5 months, from post intervention for 5 months
Effectiveness: Adverse events
時間枠:From baseline up to 5 months, from post intervention up 5 months

An adverse event is defined as a reconsult with a participating doctor or hospitalisation related to an acute respiratory tract infection or related medical problems within 30 days of the initial consultation (measured through a patient-reported outcome measure), calculated by the total number of adverse events reported by patients.

From baseline up to 5 months, from post intervention up 5 months
Implementation: Fidelity to protocol during the study
時間枠:5 months post-intervention

Fidelity will be measured qualitatively (using case study interviews) with participating doctors.

5 months post-intervention
Implementation: Doctor experiences of interventions and implementation strategies
時間枠:5 months post baseline, 5 months post intervention

User experiences will be measured qualitatively (using case study interviews), with participating doctors.

5 months post baseline, 5 months post intervention
Implementation: Practice staffs' experiences of interventions and implementation strategies
時間枠:5 months post baseline, 5 months post intervention

User experiences will be measured qualitatively (using case study interviews) with practice staff.

5 months post baseline, 5 months post intervention
Implementation: Patients' experience of interventions and implementation strategies (qualitative)
時間枠:5 months post baseline, 5 months post intervention

User experiences will be measured qualitatively (using case study interviews) with patients.

5 months post baseline, 5 months post intervention
Implementation: Change in patients' experience of interventions and implementation strategies (quantitative)
時間枠:From baseline up to 5 months, from post intervention up 5 months

Patient-reported experience measure survey will be offered to eligible patients consulting with a participating GP. Surveys include seven questions each scored from 1-4 with higher outcomes worse. The eligible range is 7-28, with higher values indicating a worse outcome.

From baseline up to 5 months, from post intervention up 5 months
Adoption: Completion of implementation modules
時間枠:Following the 5 months baseline period, and throughout the 5 months post intervention period.

Completion of implementation activity modules will be tracked using data supplied by MedCast.

Following the 5 months baseline period, and throughout the 5 months post intervention period.
Adoption: Change in the use of individual AMS interventions
時間枠:From baseline for 5 months, from post intervention for 5 months

This score is derived from the number of times an intervention is used (measured using the AMS Toolbox online form) Toolbox) per 100 consults.

The eligible range is 0-100, with higher values indicating a better outcome.

From baseline for 5 months, from post intervention for 5 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Andrew Bonney, PhD,、Graduate School of Medicine, University of Wollongong

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年7月1日

一次修了 (推定)

2027年11月30日

研究の完了 (推定)

2028年6月30日

試験登録日

最初に提出

2025年4月7日

QC基準を満たした最初の提出物

2025年4月23日

最初の投稿 (実際)

2025年5月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 2024/337
  • MRFF project 2029531 (その他の助成金/資金番号:NHMRC)
  • U1111-1319-2201 (その他の識別子:WHO)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All IPD that underlie results in a publication will be shared in-deidentified form.

IPD 共有時間枠

For IPD, data will be available from December 2029.

For supporting information, the protocol paper and statistical analysis plan will be submitted for publication by November 2025. Informed consent form is attached. Analytical code will be provided with the primary outcomes publication.

IPD and supporting data will be available at least until December 2039.

IPD 共有アクセス基準

IPD:

Supporting evidence: the protocol will be published in a peer-reviewed journal. Informed consent forms are available on request from the primary investigator or from the study website ().

Analytical code will be provided with the primary outcomes publication

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する